Monitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptide.
Knobloch
K
K
Tepe
J
J
Lichtinghagen
R
R
Luck
H J
HJ
Vogt
P M
PM
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy; D015150:Echocardiography, Doppler / Q000379:methods*; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D008991:Monitoring, Physiologic / Q000379:methods*; D020097:Natriuretic Peptide, Brain / Q000097:blood* / Q000187:drug effects; D009362:Neoplasm Metastasis / Q000188:drug therapy; D010446:Peptide Fragments / Q000097:blood* / Q000187:drug effects; D012307:Risk Factors; D000068878:Trastuzumab; D018754:Ventricular Dysfunction / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015415:Biomarkers; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D000068878:Trastuzumab